Please wait while the formulary information is being retrieved.
RYLAZE (asparaginase Erwinia chrysanthemi (recombinant)-rywn)
- acute lymphoid leukemia
- lymphoblastic lymphoma
10 mg/0.5 mL intramuscular solution
- Inject 25 mg/m2 by intramuscular route every 48 hours
Default screening record
- Inject 50 mg/m2 by intramuscular route once weekly
- Inject 25 mg/m2 by intramuscular route every 48 hours
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- Methotrexate (anti-rheumatic)
- methotrexate sodium
- methotrexate sodium (PF)
- Rheumatrex
- Trexall
Severe
Moderate
- None
- Acute pancreatitis
- Lactation
Contraindicated
- Hemorrhage
- Pregnancy
- Thromboembolic disorder
Severe
Moderate
- Abnormal hepatic function tests
- Diabetes mellitus
- Hyperbilirubinemia
- Increased risk of bleeding
RYLAZE (asparaginase Erwinia chrysanthemi (recombinant)-rywn)
- acute lymphoid leukemia
- lymphoblastic lymphoma
- Abnormal hepatic function tests
- Acute hepatic failure
- Acute pancreatitis
- Hyperglycemia
- Hypersensitivity drug reaction
- Increased risk of bleeding due to coagulation disorder
- Thrombotic disorder
- Acute abdominal pain
- Diarrhea
- Fever
- Injection site sequelae
- Musculoskeletal pain
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Elevated serum amylase
- Elevated serum lipase
- Hallucinations
- Headache disorder
- Hypoalbuminemia
- Urticaria
- Anorexia
- Cough
- Fatigue
- Hyperammonemia
- Hyperbilirubinemia
- Insomnia
- Peripheral motor neuropathy
- Peripheral sensory neuropathy
- Stomatitis
- Tachycardia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Bronchospastic pulmonary disease
- Cerebral thrombosis
- Coma
- Diabetic ketoacidosis
- Hemorrhage
- Leg vein thrombosis
- Posterior reversible encephalopathy syndrome
- Seizure disorder
Less Severe
- Dyspnea
- Hyperlipidemia
- Hypertriglyceridemia
- Pruritus of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Asparaginase Erwinia (recomb)-rywn
Safety and effectiveness not established in pediatric patients < 1 month.
- 1 Day – 29 Days
- Safety and effectiveness not established in pediatric patients < 1 month.
Asparaginase
- Severity Level:
D
- Additional Notes: Insuff data available; weigh maternal benefit vs potential fetal adverse outcome
Contraindicated
Asparaginase
Not recommended. potential for serious adverse effects on infant.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Not recommended. potential for serious adverse effects on infant. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Acute lymphoid leukemia | |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| Lymphoblastic lymphoma | |
| C83.5 | Lymphoblastic (diffuse) lymphoma |
| C83.50 | Lymphoblastic (diffuse) lymphoma, unspecified site |
| C83.51 | Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck |
| C83.52 | Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes |
| C83.53 | Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes |
| C83.54 | Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb |
| C83.55 | Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb |
| C83.56 | Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes |
| C83.57 | Lymphoblastic (diffuse) lymphoma, spleen |
| C83.58 | Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites |
| C83.59 | Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites |
| 0-9 | A-Z |
|---|---|
| C83.5 | Lymphoblastic (diffuse) lymphoma |
| C83.50 | Lymphoblastic (diffuse) lymphoma, unspecified site |
| C83.51 | Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck |
| C83.52 | Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes |
| C83.53 | Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes |
| C83.54 | Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb |
| C83.55 | Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb |
| C83.56 | Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes |
| C83.57 | Lymphoblastic (diffuse) lymphoma, spleen |
| C83.58 | Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites |
| C83.59 | Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
Formulary Reference Tool